Alzheimer’s Disease and Parkinson’s Disease: A Review of Current Treatment Adopting a Nanotechnology Approach

E-ISSN： 1873-4286|24|1|22-45

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.24, Iss.1, 2018-03, pp. : 22-45

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

6th International Conference on Alzheimer’s Disease and Parkinson’s Disease

By Lahiri Debomoy K

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1433-1440

Informa Healthcare

Access to resources Recommend Favorite

Ropinirole in the treatment of Parkinson’s disease

By Zesiewicz T.A. Hauser R.A.

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 5, 1999-05 ,pp. : 697-710

Informa Healthcare

Access to resources Recommend Favorite

Rationale for current therapies in Parkinson’s disease

By Romrell Janet Fernandez Hubert H Okun Michael S

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 10, 2003-10 ,pp. : 1747-1761

Informa Healthcare

Access to resources Recommend Favorite

Current status and new developments with galantamine in the treatment of Alzheimer’s disease

By Tariot Pierre

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 12, 2001-12 ,pp. : 2027-2049

Informa Healthcare

Access to resources Recommend Favorite

Current strategies for the treatment of Alzheimer’s disease and other tauopathies

By Dickey Chad A Petrucelli Leonard

Expert Opinion on Therapeutic Targets, Vol. 10, Iss. 5, 2006-10 ,pp. : 665-676

Informa Healthcare

Access to resources Recommend Favorite